

Sub  
A  
cont.  
mixing carbon dioxide gas with air to form a carbon dioxide-air mixture, said carbon dioxide-air mixture containing up to about 10% by volume carbon dioxide gas;

aerosolizing said drug in said carbon dioxide-air mixture wherein prior to aerosolization said drug is a soluble drug dissolved in a buffered solution or water or, in the alternative, said drug is an insoluble or lipophilic drug carried by a sterically stabilized liposome, a slow release polymer or a polycationic polymer; and

administering said aerosolized drug during inhalation therapy by continuously flowing said carbon-dioxide-air mixture wherein carbon dioxide in said mixture increases inhalation rate and inhaled volume of said aerosolized drug thereby increasing deposition of said aerosolized drug into the respiratory tract.

[ Please amend claim 2 to read as follows: ]

2 (amended). The method of claim 1, wherein said air mixture contains 2.5% by volume carbon dioxide gas.

[ Please amend claim 3 to read as follows: ]

3 (amended). The method of claim 1, wherein said air mixture contains 5% by volume carbon dioxide gas.

a

A1  
[ Please amend claim 4 to read as follows: ]

4 (amended). The method of claim 1, wherein said air mixture contains 7.5% by volume carbon dioxide gas.

---

Please amend claim 8 to read as follows:

---

A2  
4 ~~8~~ (amended). The method of claim 1, wherein said water soluble or buffer soluble drug is selected from the group consisting of an antibiotic, a mucolytic, a bronchodilator, a parasympathetic agent, an enzyme and an anti-viral.

---

Please amend claim 14 to read as follows:

---

5 ~~14~~ (amended). The method of claim 1, wherein said sterically stabilized liposome is a poly(ethylene glycol) modified phospholipid.

A3  
[ Please amend claim 15 to read as follows: ]

6 ~~15~~ (amended). The method of claim ~~14~~ <sup>5</sup>, wherein said poly(ethylene glycol) modified phospholipid is dimyristoylphosphoethanolamine poly(ethylene glycol) 2000.

---

Please amend claim 17 to read as follows:

**7** ~~17~~ (amended). The method of claim 1, wherein said lipophilic drug is selected from the group consisting of amphotericin B, nystatin, glucocorticoids, an immunosuppressive and an anti-cancer drug.

**Q4** Please amend claim 18 to read as follows:

**8** ~~18~~ (amended). The method of claim ~~17~~ <sup>7</sup>, wherein said anti-cancer drug is selected from the group consisting of camptothecin, 9-nitrocamptothecin, and paclitaxel.

Please amend claim 21 to read as follows:

**As** **11** ~~21~~ (amended). The method of claim ~~19~~ <sup>7</sup>, wherein said DNA gene is delivered via a polycationic polymer carrier.

Please amend claim 23 to read as follows:

**Al** **B** ~~23~~ (amended). The method of claim ~~22~~ <sup>12</sup>, wherein a ratio of polyethylenimine nitrogen to DNA phosphate (nitrogen:phosphate) is about 10:1 to about 20:1.